Michael Makris/LinkedIn
Jun 18, 2026, 06:43
Michael Makris: Will New Anti-TFPI Drug Armocibat Behaves any Different to Concizumab or Marstacimab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn:
“A Chinese company called Suzhou Alphamab is making an anti-TFPI drug called armocibat, for use in haemophilia with and without inhibitors.
The drug is in phase III at present.
They have just signed a license agreement for a Russian company called Nanolek to produce the drug.
I have no reason to believe that armocibat behaves any different to concizumab or marstacimab, but I hope they have safety surveillance systems to monitor for thrombosis when this drug is no longer in clinical trials.”
Stay updated with Hemostasis Today.
-
Jun 18, 2026, 03:00Daniel Ben-Mordechay: Portal Vein Thrombosis – Recognizing a Potentially Life-Threatening Diagnosis with Ultrasound
-
Jun 18, 2026, 00:32Nibal Chamoun: Excited to Co-Moderate the Antithrombotic Stewardship Summit at ISTH 2026
-
Jun 17, 2026, 22:28Muntadhar Al Moosawi: A Tribute to the Compassion and Generosity of Cleveland Clinic Abu Dhabi’s Blood Donors
-
Jun 17, 2026, 20:06Hossam El Benawi: Who Can Safely Stop Anticoagulation after LVT Resolution?
-
Jun 17, 2026, 17:47Anuoluwapo Oladunjoye: Every Blood Film Has a Story to Tell
-
Jun 17, 2026, 17:46Svetislav Matic: A Patient-Centric Interdisciplinary Approach to Perioperative Bleeding Management
-
Jun 17, 2026, 17:45Paul Breillat: New Insights Into the Role of RIPK1-Mediated Cell Death in VEXAS syndrome
-
Jun 17, 2026, 17:44Konstantin Yenkoyan: New Publication Alert – Autism and Iron Dysregulation
-
Jun 17, 2026, 17:44Ifeanyichukwu Ifechidere: Why Fibrinolysis Matters as Much as Clot Formation